SAN FRANCISCO, January 06, 2022–(BUSINESS WIRE)–Alumis, formerly Esker Therapeutics, a precision immunology company backed by Foresite Capital and incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the completion of a $200 million financing led by AyurMaya, an affiliate of Matrix Capital Management, and by a U.S.-based healthcare-focused fund. In conjunction with the financing, Alumis announced that Dr. Alan Colowick, managing director at Matrix, joined the company’s board of directors.
"We are thrilled to announce the completion of this financing with support from leading investors in our industry. These funds position us well to independently advance several precision immunology programs and potentially add additional assets to our pipeline," said Martin Babler, president and chief executive officer of Alumis. "Since the company’s launch last year, we have been making progress advancing our lead program into the clinic, initiating several pipeline programs and leveraging insights from our analytics platform to inform both our clinical development plans and our discovery programs. Our team has expanded significantly in research, development and business development, and we are pleased to further strengthen our board of directors with industry veterans such as Alan Colowick. I look forward to collaborating with our team and board as we work to deliver precision therapies to patients in need."
Proceeds from the financing will be used to continue to advance Alumis’ pipeline, led by ESK-001, a highly selective and potentially best in class TYK2 inhibitor with greater selectivity for TYK2 over JAK1 compared to current therapies in clinical development. ESK-001 is currently being developed for the treatment of psoriasis. Beyond ESK-001, Alumis is using its data analytics and research capabilities to build a pipeline from internal and external sources focused on delivering precision immunology therapies impacting the causal drivers of multiple autoimmune disease indications.
"Alumis’ unique approach of combining a novel precision analytics platform with deep experience in immunology pathophysiology and a proven track record of developing and commercializing novel drugs holds significant promise for the future treatment of patients with autoimmune disease," said Dr. Colowick. "Alumis is a perfect fit for our mission to support world class teams focusing on addressing the most important unmet medical needs by leveraging the convergence of technology and biology. I am particularly excited to join the board of directors and to have the opportunity to work with Martin and his team again."
"This is an exciting time for the team at Alumis and the patients with autoimmune diseases who are waiting for new therapies," said Jim Tananbaum, founder and CEO of Foresite Capital. "This additional financing will help Alumis develop a comprehensive data set for people suffering from autoimmunity driven by TYK2 and other development targets."
The company’s name change to Alumis ("alumer" for "lighten/enlightened" and "immunis" for "immunology") is reflective of the transformation of the organization and overall vision to provide meaningful therapeutic solutions for people with autoimmune disease.
About Alumis
Alumis is a precision immunology company looking to eliminate the "all comer" approach that is seen with today’s treatments for people with autoimmune disease. Even with innovation of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Alumis leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug discovery, development and immunology, in order to create medicines that change the lives of people with autoimmune disease. For more information, please visit alumis.co.
About Foresite Labs
Foresite Labs incubates companies that will address some of our greatest unmet medical needs. Their experienced team of scientists, engineers, and operators believes that the tools of data science, when applied with scientific rigor, will greatly accelerate scientific discovery and the development of new products and services that benefit patients. Through its incubation platform, Foresite Labs is dismantling the barriers faced by visionary entrepreneurs and their companies as they seek to re-invent healthcare. For more information, visit www.foresitelabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005281/en/
Contacts
Dan Budwick, 1AB
dan@1abmedia.com
Have an issue with your financial adviser or have questions about hiring a new one? Email picks@marketwatch.com.
Shares of cruise line operator Carnival Corporation (NYSE: CCL)(NYSE: CUK) fell 2.6% on Monday, which may not seem like very much. According to The Fly, analysts Brandt Montour, Benjamin Chaiken, and Christopher Stathoulopoulos — of Barclays, Credit Suisse, and Susquehanna, respectively — all lowered their price targets for Carnival this morning.
The debt crisis is here, Nouriel Roubini says. Expect central banks to wimp out in their fight against inflation as financial distress deepens
Former President Donald Trump on Monday sued CNN, seeking $475 million in damages, saying the network had defamed him in an effort to short-circuit any future political campaign.
High-yield savings accounts are paying more than they have since 2009. Here's Cuban's advice on how much to save now.
Incumbent chip maker Intel (NASDAQ: INTC), a banner victim of this year's tech stock sell-off, had an unusually good Monday. The company's shares rose by almost 5% on the day, due in part to a general rebound of tech titles generally and chip makers specifically, and partly due to a looming divestment. After market hours on Friday, Intel's assisted- and autonomous-driving tech unit Mobileye filed a prospectus for an initial public offering (IPO).
The catalyst that sent the electric vehicle (EV) maker plunging was quarterly vehicle deliveries that fell short of expectations. In a press release that dropped Sunday, Tesla revealed its third-quarter production and delivery numbers, and while the growth was robust, investors wanted more. In its press release, Tesla addressed the issue, saying, "Historically, our delivery volumes have skewed toward the end of each quarter … [but] as our production volumes continue to grow, it is becoming increasingly challenging to secure vehicle transportation capacity."
Tesla shares are getting hammered after weaker-than-expected third-quarter delivery numbers. The reason isn't 'cars in transit.'
Shares of large-cap oil and gas producers Chevron (NYSE: CVX), Occidental Petroleum (NYSE: OXY), and Devon Energy (NYSE: DVN) were in rally mode today, up 5%, 5.4%, and 7.9%, respectively, as of 11:24 a.m. ET. While many stocks were higher today, oil and gas stocks were particularly strong ahead of the upcoming OPEC+ meeting this week. Over the weekend, The Wall Street Journal reported OPEC+ participants would discuss production cuts at the upcoming meeting to offset falling prices, with the potential for a surprisingly large cut in the offing.
Over the weekend, the South American nation held the first round of its 2022 presidential election, and former President Luiz Inacio Lula da Silva was ahead in the polling — and investors are cheering. As of 10:45 a.m. ET Monday, shares of Brazilian oil giant Petroleo Brasileiro (NYSE: PBR) (NYSE: PBR.A) (aka Petrobras) were up 12.4%, while electric and gas utility Companhia Energetica de Minas Gerais (NYSE: CIG) had gained 14.6%, and water utility Companhia de Saneamento Basico do Estado de Sao Paulo (NYSE: SBS) (aka "Sabesp") was leading the whole Brazilian stock market higher with a 22.5% gain.
Berkshire Hathaway Vice Chairman Greg Abel, the likely successor to CEO Warren Buffett, bought about $68 million of the company’s shares last Thursday in what appears to be his first purchases of Berkshire stock since he assumed the position in 2018. In several Form 4 filings Monday with the Securities and Exchange Commission, Abel disclosed that he purchased 168 Berkshire Hathaway (ticker: BRK/A, BRK/B) Class A shares through the Gregory Abel Revocable Trust on behalf of his wife, children, and other family members. Abel paid in a range of roughly $405,000 to $408,000 per class A share for the Berkshire stock, which closed Monday at $413,300, up 1.7% on the session.
Tesla (TSLA) stock could get a lift from ESG asset managers — if only they could agree on the company's status.
Recently, Zacks.com users have been paying close attention to Medical Properties (MPW). This makes it worthwhile to examine what the stock has in store.
'I’m about as bearish as I’ve been since 2008,' says Hedgeye's Keith McCullough. He's steering investors to cash, gold and other defensive plays.
How does the Fed affect the rest of us? Here's an explainer, and when to expect lower prices for groceries, possibly higher unemployment, and what you can do for now
Shares of e-commerce platform provider Shopify (NYSE: SHOP) rose as much as 3.2%, semiconductor specialist Nvidia (NASDAQ: NVDA) jumped as much as 3.7%, and streaming video pioneer Roku (NASDAQ: ROKU) surged as much as 4.3%. The latest report on manufacturing data provided investors with the excuse they were looking for to buy shares of beaten-down technology stocks. The Manufacturing Purchasing Managers Index (PMI) came in at 50.9%, down from 52.8% in August.
Shares of precious metals stocks, however, are looking especially lustrous in investors' eyes thanks to companies receiving favorable coverage from Wall Street and silver and gold prices rising higher. As of 11:15 a.m. ET, shares of New Gold (NYSEMKT: NGD) are up 13.4%, while Endeavour Silver (NYSE: EXK) and Coeur Mining (NYSE: CDE) have risen 11.6% and 15.1%, respectively. Believing that New Gold's stock has room to run, Michael Siperco, an analyst at RBC Capital, raised his price target on the company's stock to $1.25 from $1.
Rivian on Monday said it believes it is still on pace to produce 25,000 vehicles this year, despite earlier production setbacks for the electric-vehicle maker. Shares jumped 10% after hours. Management said the company produced 7,363 vehicles in the third quarter. The electric-vehicle maker said those vehicles were produced at its plant in Normal, Ill., and that it delivered 6,584 vehicles during the quarter. The totals, management said, remained in line with current expectations.
Oppenheimer Sr. Research Analyst Colin Rusch joins Yahoo Finance Live to discuss third-quarter production for Tesla, vehicle deliveries, inflationary pressures, supply chain woes, recessionary risks, and the outlook for the automotive company.
Verizon deployed drones over Sanibel Island to provide temporary cell service, help assess damages and expedite recovery efforts after Hurricane Ian. The drone provides coverage for an approximate 5-7 mile radius and can fly for up to 1,000 hours.